Live
One Link Live rooms, co-hosting, captions, gifts and community tools.

OneLinkUS
GHOST OMNI DIVINE IS GOD LLC
OneLinkUS.com
Sign in with an existing subscription to unlock visual layouts.
Browse worldwide headlines, search any country or region, and choose a topic. Publisher photographs and video appear when available from the news source.
Explore news by country, topic and format →Headlines from publishers around the world. Search any country, region or topic.
No headlines found. Try a broader topic.
More world news →16 results for “United States Covid: US approves Moderna as second vaccine - BBC live news”
Showing OneLink and reference results. Broader web, photo and video coverage is awaiting the search provider connection.
One Link Live rooms, co-hosting, captions, gifts and community tools.
Worldwide problem-solving, official services, emergency guidance and reliable next steps.
Reading, math, physics, science, coding, languages, business, life skills and more.
OneLinkUS games, game learning, strategy and accessible play.
Products, books, clothing and OneLinkUS merchandise.
OneLinkUS books and writings.
Product design, assistive machines, solar energy shade and weather protection concepts.
Sign in, create an account, reset your password or manage your OneLinkUS session.
Help using OneLinkUS and contact support.
Advanced platform connections, AI, backend and service status.
A COVID‑19 vaccine is designed to induce immunity against SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19). COVID-19 vaccines help reduce the risk of severe illness, hospitalization and death from the virus.
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax among others, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months, twelve years, or eighteen years and older.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1.
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. Updated versions of the vaccine have been developed to provide coverage against the Omicron variant, with different formulas for 2023–2024 (containing a recombinant spike protein from lineage XBB.1.5) and 2024–2025 (containing recombinant spike pro
The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson. It is a viral vector vaccine based on a human adenovirus that has been modified to contain the gene for making the spike protein of the SARS-CoV-2 virus that causes COVID‑19.
As of 12 August 2024, 13.53 billion COVID-19 vaccine doses have been administered worldwide, with 70.6 percent of the global population having received at least one dose. While 4.19 million vaccines were then being administered daily, only 22.3 percent of people in low-income countries had received at least a first vaccine by September 2022, according to official reports from national health agencies, which are collated by Our World in Data.